What does this research mean for the field?

Ductal carcinoma in situ (DCIS) management must transition from aggressive overtreatment to precision-based clinical standards that reflect its non-invasive, non-metastatic nature. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The aim is to redefine management approaches for ductal carcinoma in situ, focusing on precision rather than overtreatment.

March 22, 2026Open Access

From overtreatment to precision: a new clinical standard for DCIS management

Key Points

The aim is to redefine management approaches for ductal carcinoma in situ, focusing on precision rather than overtreatment.
Conducted a literature review on DCIS diagnosis and treatment approaches.
Analyzed current clinical standards and their implications for patient outcomes.
Evaluated the biological characteristics of DCIS and its impact on treatment decisions.
Highlighted the non-invasive nature of DCIS and its limited metastatic potential.
Demonstrated that the labeling of DCIS as 'breast cancer' may lead to unnecessary overtreatment.
Suggested precision management strategies that could reduce patient anxiety and improve quality of care.

Abstract

Ductal carcinoma in situ (DCIS) remains one of the most conceptually challenging diagnoses in breast oncology. DCIS is technically non-invasive, contained within the basement membrane, and lacks metastatic potential in its pure form. Yet patients are told that they have “breast cancer,” a term

Bookmark

View Full Paper

Bookmark

View Full Paper

From overtreatment to precision: a new clinical standard for DCIS management

Key Points

Abstract

Cite This Study